MAGI1-AS1: A Potential Drug Target and Biomarker (G100873983)

Target Name: MAGI1-AS1

NCBI ID: G100873983

MAGI1-AS1

Other Name(s): MAGI1 antisense RNA 1

MAGI1-AS1: A Potential Drug Target and Biomarker

MAGI1-AS1, a gene encoding a protein known as MAGI1-AS1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MAGI1-AS1 functions as a transcription factor, regulating gene expression and cell growth. The research on MAGI1-AS1 has generated significant interest in the development of new therapeutic strategies for these diseases.

MAGI1-AS1 and Cancer

Cancer is a leading cause of human death worldwide, with over 20 million new cases and 5.5 million deaths in 2020, according to the World Health Organization (WHO). The development of new cancer therapies is crucial for the treatment of this disease. MAGI1-AS1 has been shown to play a critical role in cancer development and progression.

Studies have shown that MAGI1-AS1 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancers. It has also been found to be involved in the regulation of cell cycle progression and the execution of apoptosis, which is a process responsible for cell death in response to DNA damage or other stimuli. MAGI1-AS1 has been shown to promote the survival of cancer cells by regulating cell apoptosis and promoting the growth and proliferation of cancer cells.

MAGI1-AS1 and Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are progressive neurological disorders that affect the brain and nervous system. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurogenic markers. MAGI1-AS1 has been shown to be involved in the development and progression of neurodegenerative diseases.

Studies have shown that MAGI1-AS1 is expressed in the brains of individuals with Alzheimer's disease and Parkinson's disease. It has also been found to be involved in the regulation of neurogenesis, which is the process by which new neurons are generated in the brain. MAGI1-AS1 has been shown to promote neurogenesis and protect against the loss of brain cells in neurodegenerative diseases.

MAGI1-AS1 and Autoimmune Disorders

Autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are chronic autoimmune diseases that affect the immune system and result in inflammation and damage to various body parts. MAGI1-AS1 has been shown to be involved in the development and progression of autoimmune disorders.

Studies have shown that MAGI1-AS1 is expressed in the immune cells of individuals with rheumatoid arthritis and lupus. It has also been found to be involved in the regulation of immune cell function and the development of autoimmune diseases. MAGI1-AS1 has been shown to promote the development and progression of autoimmune disorders by regulating immune cell function and promoting the production of autoantibodies.

MAGI1-AS1 as a Drug Target

The development of new drug targets is a critical step in the development of new therapeutic strategies for various diseases. MAGI1-AS1 has been identified as a potential drug target due to its involvement in the regulation of cell cycle progression, apoptosis, and immune cell function. The research on MAGI1-AS1 has generated significant interest in the development of new therapeutic strategies for cancer, neurodegenerative diseases, and autoimmune disorders.

MAGI1-AS1 as a Biomarker

MAGI1-AS1 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The detection and quantification of MAGI1-AS1 have been shown to be involved in the diagnosis and prognosis of these diseases.

MAGI1-AS1 has been shown to be involved in

Protein Name: MAGI1 Antisense RNA 1

The "MAGI1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGI1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets